Fig. 1 · Structure

Documents & Downloads

Hesperidin

Cat. No. A10450 CAS 520-26-3
Hesperidin is a flavanone glycoside found abundantly in citrus fruits.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In HeLa cells, 48-hour hesperidin exposure was associated with apoptotic nuclear changes, DNA fragmentation and increased CHOP, GRP78 and cleaved caspase-3. These findings associate ER stress markers with apoptosis; they do not establish a direct binding target or causal requirement for ER stress. [1]

Hesperidin responses depend on the experimental model. In HepG2 cells exposed to 1 mM, one study reported paraptosis-like vacuolation and organelle swelling, no detected active caspase-3 or cleaved PARP, and no viability rescue by z-VAD.fmk. U0126 reduced ERK phosphorylation and the vacuolated phenotype, supporting ERK pathway involvement under those conditions. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 100 μM Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction assay [PMID: 20413315]
DLD-1 IC50 > 100 μM Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction assay [PMID: 20413315]
H9 EC50 > 164 μM Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay [PMID: 8158164]
H9 IC50 > 164 μM Cytotoxicity against human H9 cells after 3 days [PMID: 8158164]
HT-29 IC50 142 μM Anticancer activity against human HT-29 cells after 72 hrs by MTT assay [PMID: 19054677]
Monocyte IC50 > 200 μM Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA [PMID: 10096854]

Hesperidin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Hesperidin from 3 published references. In vitro models include human HeLa cervical cancer and HT-29 colon cancer cell lines (ATCC); human HeLa cervical cancer cells (ATCC).

Hesperidin In Vitro Studies

In dose/time experiments spanning 20–100 μM and 24–72 hours, hesperidin reduced MTT viability in HeLa and HT-29 cancer cells, with the strongest effects at higher concentrations and longer exposures. The 20 μM bars were not marked significant. The authors reported HeLa viability of 12% of control at 100 μM after 72 hours. MTT viability is distinct from an IC50 or evidence of cancer-cell selectivity. [1]

Hesperidin decreases MTT viability in HeLa and HT-29 cells

Cell-based study · Human HeLa cervical cancer and HT-29 colon cancer cell lines (ATCC) [1]

MTT signal declined with increasing concentration and exposure time relative to the 0 μM control. The reported 12% result is for HeLa at 100 μM after 72 h; no IC50 is supplied here. MTT is a metabolic viability endpoint rather than a direct proliferation count. The 20 μM bars are not marked statistically significant in Figure 1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HeLa relative cell viability at 100 μM for 72 hMTT viability relative to 0 μM control 12% of control[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 20, 40, 60, 80 and 100 μM
Exposure duration
24, 48 or 72 h
Method
Cell treatment followed by MTT assay; background from cell-free medium subtracted.
Reported limits
Treatment solvent and final treatment-vehicle concentration are not specified in the read Methods. DMSO used to dissolve MTT formazan is not evidence of treatment vehicle.
Methods and source locations

Compound reported in the paper: Hesperidin; Compound label in the paper: HES

Literature findings for hesperidin in the stated model; no Adooq product or lot performance validation.

Methods: Chemicals and reagents; Cell culture; MTT cell proliferation assay; Results: HES-induced morphological changes and anti-proliferation effect; Figure 1b,d

HeLa relative cell viability at 100 μM for 72 h: MTT; six wells per group; assay repeated three times; mean ± SEM is the stated reporting convention. — Results: HES-induced morphological changes and anti-proliferation effect (last paragraph); Figure 1b; Methods: MTT cell proliferation assay

Apoptosis-associated phenotype and ER stress markers in HeLa cells

Cell-based study · Human HeLa cervical cancer cells (ATCC) [1]

After 48 h, hesperidin was associated with condensed nuclei, DNA fragmentation and increased CHOP, GRP78 and cleaved caspase-3. These observations support an apoptosis-associated ER stress response; they do not establish a direct molecular target or prove ER stress is required for cell death.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CHOP, GRP78 and cleaved caspase-3 abundance at 40 μM for 48 h versus controlβ-actin-normalized protein abundance (qualitative direction) Increased CHOP, GRP78 and cleaved caspase-3 relative to 0 μM cells[1]
Nuclear condensation and DNA fragmentationQualitative apoptosis-associated readouts Condensed nuclei after treatment; increased DNA fragmentation at 80 and 160 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 40, 80 and 160 μM
Exposure duration
48 h
Method
Hoechst 33342 nuclear staining, DNA laddering and immunoblotting versus 0 μM cells.
Reported limits
Treatment vehicle is unspecified. No ER-pathway genetic perturbation or selective ER-stress rescue is demonstrated by these adopted experiments.
Methods and source locations

Compound reported in the paper: Hesperidin; Compound label in the paper: HES

Literature findings for hesperidin in the stated model; no Adooq product or lot performance validation.

Methods: apoptosis detection and Western blot analysis; Results: HES-induced apoptosis; DNA fragmentation; HES increased the levels of GADD153/CHOP...; Figures 2a,b, 3, 7

CHOP, GRP78 and cleaved caspase-3 abundance at 40 μM for 48 h versus control: Immunoblot; mean ± SEM of at least three experiments; Figure 7 denotes p < 0.05 versus 0 μM. Exact fold values are not adopted because cleaved caspase-3 differs between prose and the figure. — Figure 7 printed band ratios and caption; Methods: Western blot analysis

Nuclear condensation and DNA fragmentation: Hoechst staining and DNA gel electrophoresis; no exact apoptosis fractions extracted from plots. — Figures 2a,b and 3; corresponding Results paragraphs

Paraptosis-like cell death and ERK-associated modulation in HepG2 cells

Cell-based study · Human HepG2 cells from Korean Cell Line Bank [2]

At 1 mM, hesperidin produced cytoplasmic vacuoles and mitochondrial/ER swelling without typical apoptotic nuclear changes. Active caspase-3 and cleaved PARP were not detected, and z-VAD.fmk did not rescue MTT viability. U0126 reduced ERK phosphorylation and the vacuolated phenotype. The authors describe this as paraptosis-like death.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apoptotic-marker and caspase-inhibitor assessmentQualitative mechanism controls No detected active caspase-3 or cleaved PARP; z-VAD.fmk did not restore viability[2]
ERK phosphorylation and vacuolated ultrastructure with U0126Pharmacological pathway modulation U0126 reduced hesperidin-associated pERK1/2 and cytoplasmic vacuolation/mitochondrial–ER swelling[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM hesperidin; DAPI series also includes 0.1 and 2 mM
Exposure duration
24 h for immunoblots and caspase-inhibitor MTT; TEM at 24 and 48 h
Method
Vehicle-controlled cell treatment with ultrastructure, DNA gel, immunoblot and inhibitor controls.
Vehicle
1% DMSO
Co-treatment
Mechanistic controls: z-VAD.fmk 20 μM for 1 h before hesperidin; U0126 10 μM for 2 h before hesperidin (not therapeutic combinations).
Reported limits
No direct hesperidin binding target or genetic ERK validation established. Negative caspase blots lack an apoptotic positive-control lane in the viewed Figure 5A.
Methods and source locations

Compound reported in the paper: Hesperidin; Compound label in the paper: hesperidin

Literature findings for hesperidin in the stated model; no Adooq product or lot performance validation.

Materials and Methods: Cell Culture and Treatment, Electron Microscopy, DNA Fragmentation, Western blot, Inhibitor assay; Results; Figures 3, 5A–B, 6

Apoptotic-marker and caspase-inhibitor assessment: Figure 5A immunoblot and 5B MTT; mean ± SD of three replicate independent experiments as captioned. No numerical rescue magnitude inferred. — Figure 5A–B and Results: Hesperidin induced cell death is caspase independent

ERK phosphorylation and vacuolated ultrastructure with U0126: Immunoblot with β-actin loading control; TEM. Pharmacological evidence supports involvement, not direct target inhibition by hesperidin. — Figure 6A–B; Figure 3B a–f; Results: Involvement of ERK1/2 MAPK in paraptosis

Hesperidin In Vivo Studies

In a female BALB/c allergic-asthma model, oral hesperidin at 5 mg/kg over five weeks reduced the methacholine-induced Penh response relative to the allergen-challenged vehicle control. The 1 mg/kg group showed no significant reduction. Dosing frequency is described inconsistently in the paper. These results concern a plethysmographic mouse endpoint and do not establish clinical efficacy. [3]

Dose-dependent limits of hesperidin on airway response in allergic-asthma mice

Animal study · Female BALB/c mice; five weeks old at acquisition; ovalbumin allergic-asthma model [3]

Hesperidin at 5 mg/kg reduced the methacholine-induced Penh response, whereas 1 mg/kg did not significantly differ from OVA-challenged controls. Penh is a whole-body plethysmography endpoint; it does not directly establish airway resistance or clinical efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Methacholine-induced Penh responseWhole-body plethysmography 5 mg/kg: reduced response versus OVA control; 1 mg/kg: no significant difference[3]

Conditions shared by the study groups

Route
Oral
Frequency
Reported as three times/week in Methods 2.2 and Figure 1a; five times/week in histology Section 2.6. Actual frequency unresolved.
Treatment course
Last 5 weeks of the model protocol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Hesperidin 5 mg/kgOVA + vehicle control; normal mice and formoterol comparator also includedReduced methacholine-induced Penh versus OVA + vehicle controls at the marked higher challenge concentrations (Figure 1b; p < .05 or p < .01).[3]
Hesperidin 1 mg/kgOVA + vehicle control; normal mice and formoterol comparator also includedNo statistically significant reduction of methacholine-induced AHR versus OVA + vehicle controls was reported (Results 3.1).[3]
Hesperidin 5 mg/kg
Model: Female BALB/c mice in an ovalbumin allergic-asthma model
Reported limits: Vehicle composition is unspecified; conflicting frequency descriptions prevent an unqualified regimen claim.
Hesperidin 1 mg/kg
Model: Female BALB/c mice in an ovalbumin allergic-asthma model
Reported limits: Vehicle composition is unspecified; conflicting frequency descriptions prevent an unqualified regimen claim.
Methods and source locations

Compound reported in the paper: Hesperidin; Compound label in the paper: HPN

Literature findings for hesperidin in the stated model; no Adooq product or lot performance validation.

Methods 2.1–2.2, 2.5, 2.11; Results 3.1; Figure 1a–b

Methacholine-induced Penh response: Buxco system; reported significance at 5 mg/kg p < .01 or p < .05; no curve decimals extracted. — Results 3.1 and Figure 1b; Methods 2.5

Hesperidin 5 mg/kg · Methods 2.1–2.2, 2.5, 2.11; Results 3.1; Figure 1a–b

Hesperidin 1 mg/kg · Methods 2.1–2.2, 2.5, 2.11; Results 3.1; Figure 1a–b

Specifications

Manufacturer Adooq Bioscience
CAS Number 520-26-3
Formula C28H34O15
Molecular Weight 610.6
Synonyms Vitamin P
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 97 mg/mL (158.87 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Hesperidin Research References

  1. [1] Wang Y, Yu H, Zhang J, et al. Hesperidin inhibits HeLa cell proliferation through apoptosis mediated by endoplasmic reticulum stress pathways and cell cycle arrest BMC Cancer (2015). PMID: 26459308 DOI: 10.1186/s12885-015-1706-y Source material
  2. [2] Yumnam S, Park HS, Kim MK, et al. Hesperidin Induces Paraptosis Like Cell Death in Hepatoblastoma, HepG2 Cells: Involvement of ERK1/2 MAPK PLoS One (2014). PMID: 24977707 DOI: 10.1371/journal.pone.0101321 Source material
  3. [3] Kim SH, Kim BK, Lee YC. Antiasthmatic Effects of Hesperidin, a Potential Th2 Cytokine Antagonist, in a Mouse Model of Allergic Asthma Mediators Inflamm (2011). PMID: 21772663 DOI: 10.1155/2011/485402 Source material

Added to your cart

View Cart Checkout
Loading...